Drugs in Pipeline
8
Phase 3 Programs
4
Upcoming Catalysts
4
Next Catalyst
Aug 15, 2026
| Drug Name | Phase |
|---|---|
FAI insert | Phase 3 |
Sham Injection | Phase 3 |
FAI Insert administered using the Mk II inserter | Phase 3 |
Aflibercept (2.0 mg) | Phase 3 |
AKB-9778 | Phase 2 |
Aflibercept 2mg/0.05mL Inj,Oph | Phase 2 |
EYP-1901 | Phase 2 |
Latanoprost ophthalmic solution | Phase 2 |
4 upcoming, 0 past
Primary completion for Aflibercept (2.0 mg) trial (NCT06668064) in Wet Age Related Macular Degeneration
SourcePrimary completion for EYP-1901 trial (NCT06668064) in Wet Age Related Macular Degeneration
SourcePrimary completion for Aflibercept (2.0 mg) trial (NCT06683742) in Wet Age Related Macular Degeneration
SourcePrimary completion for EYP-1901 trial (NCT06683742) in Wet Age Related Macular Degeneration
Source